Clinical trials: Leishmaniasis
Leishmaniasis
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Leishmanias is a disease caused by the bite of sandflies and is found in many parts of the world including the Europe, Southwest Asia, Africa and the Middle East.
- Trial name
- NCT00657618
- Testing
- Sodium Stibogluconate (SSG)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis, Cutaneous
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).
- Trial name
- NCT01032382
- Testing
- WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream)
- Where
- Peru
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis, Cutaneous
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).
- Trial name
- NCT01083576
- Testing
- WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream)
- Where
- Panama
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in subjects with CL in Panama.
- Trial name
- NCT01790659
- Testing
- WR 279,396, Paromomycin
- Where
- Panama
- Volunteers
- 399 people
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
This study will test the ability of the topical cream WR 279,396 to treat the skin lesions caused by the parasite called leishmania. WR 279,396 is an antibiotic preparation that contains paromomycin + gentamicin.
- Trial name
- NCT00606580
- Testing
- WR 279,396 topical cream, Paromomycin Alone topical cream
- Where
- Tunisia
- Volunteers
- 375 people
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
This study is to determine the effectiveness and safety of WR 279,396, a topical cream for the treatment of cutaneous leishmaniasis.
- Trial name
- NCT00703924
- Testing
- WR 279,396
- Where
- 2 sites in France, Tunisia
- Volunteers
- 92 people
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis
Sodium Stibogluconate Treatment of Leishmaniasis
Leishmanias is a disease caused by the bite of sandflies and is found in many parts of the world including the Europe, Southwest Asia, Africa and the Middle East.
- Trial name
- NCT00662012
- Testing
- Sodium Stibogluconate (SSG)
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- U.S. Army Medical Research and Development Command